Skip to main content

Table 3 Multivariable analysis of factors affecting antibody titers in the Control group

From: Investigation for the efficacy of COVID-19 vaccine in Japanese CKD patients treated with hemodialysis

Variable

Estimate

Standard variation

p value

VIF

Antibody titer at 2 weeks (multivariable regression analysis)

Age

− 0.01

0.01

0.15

1.18

DM

− 0.20

0.12

0.10

1.05

COPD

0.32

0.19

0.09

1.02

BUN

− 0.02

0.02

0.27

1.20

Cerebrovascular disease

− 0.30

0.23

0.19

1.02

Antibody titer at 2 weeks (stepwise regression analysis)

Age

− 0.02

0.01

0.005

1.00

DM

− 0.26

0.12

0.04

1.02

COPD

0.32

0.16

0.05

1.02

Reduction rate of antibody titer (multivariable regression analysis)

BMI

0.06

0.03

0.05

1.12

Alb

− 0.60

0.38

0.12

1.61

Sex

− 0.06

0.14

0.69

1.22

Age

− 0.01

0.01

0.44

1.22

CRP

0.09

0.63

0.89

1.44

IgG

− 0.0001

0.0004

0.88

1.51

UA

0.10

0.10

0.29

1.15

Reduction rate of antibody titer (stepwise regression analysis)

BMI

0.07

0.03

0.03

1.00

Alb

− 0.49

0.30

0.11

1.00

  1. VIF, variance inflation factor; DM, diabetes mellitus; COPD, chronic obstructive pulmonary disease; BUN, blood urea nitrogen; BMI, body mass index; Alb, albumin; CRP, C-reactive protein; IgG, immunoglobulin G; UA, uric acid; 
  2. Statistically significant parts with p < 0.05 were shown in bold